{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T11:34:22Z","timestamp":1793100862388,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>When decision makers use evidence from a randomized trial to inform population-level decisions, the target population they envision rarely aligns with the population of individuals who enrolled in the trial. Here, we extend inferences from the VALIDATE-SWEDEHEART randomized trial (hereafter, the index trial), which compared the effects of bivalirudin and heparin during percutaneous coronary intervention on the risk of death, reinfarction, and bleeding, to two clinically relevant target populations: first, the trial-eligible population of individuals eligible for the index trial regardless of enrollment, and second, the treatment-candidate population of individuals who are considered candidates for bivalirudin and heparin under routine care, regardless of eligibility for the index trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Using data from the index trial, we fit logistic regression models for the outcome at 180 days in each group based on assigned treatment. We then standardized risk estimates to the baseline covariate distribution of the trial-eligible and treatment-candidate target populations, which were characterized using data from Swedish healthcare registries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The estimated risk difference comparing bivalirudin versus heparin was \u22121.1% (\u22123.1%, 0.9%) in the trial-eligible population and \u22121.0% (\u22123.0%, 1.0%) in the treatment-candidate population. The corresponding risk ratios were 0.92 (0.80, 1.07) and 0.93 (0.80, 1.07), respectively, aligning closely with estimates from the index trial. Absolute risks in each treatment group were, however, between 0.8 and 1.2 percentage points higher in comparison with the index trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Estimated risk ratios for the broader trial-eligible and treatment-candidate populations generally align with the findings from the index trial. While trials provide essential evidence for healthcare, questions often arise about wider, clinically relevant populations beyond the population of trial participants. By leveraging data from trials and observational data sources, we can attempt to address questions in these wider target populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ede.0000000000001994","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:00:37Z","timestamp":1777928437000},"page":"603-611","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Extending Inferences from a Randomized Trial to Trial-eligible and Treatment-candidate Target Populations: Examples of Generalizability and Transportability"],"prefix":"10.1097","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2655-192X","authenticated-orcid":false,"given":"Jessica C.","family":"Young","sequence":"first","affiliation":[{"name":"Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Real-World Evidence & Analytics, Quantify Research, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa J.","family":"Dahabreh","sequence":"additional","affiliation":[{"name":"CAUSALab, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA"},{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA"},{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Erlinge","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden"},{"name":"Department of Cardiology, Sk\u00e5ne University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Fr\u00f6bert","sequence":"additional","affiliation":[{"name":"Faculty of Health, Department of Cardiology, \u00d6rebro University, \u00d6rebro, Sweden"},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark"},{"name":"Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Berglund","sequence":"additional","affiliation":[{"name":"Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Rylance","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Hern\u00e1n","sequence":"additional","affiliation":[{"name":"Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"CAUSALab, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA"},{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"R1-20261027","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/aje\/kwae129","article-title":"Identifying target populations to align with decision-makers\u2019 needs.","volume":"193","author":"Lund","year":"2024","journal-title":"Am J Epidemiol"},{"key":"R2-20261027","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11121-014-0513-z","article-title":"Assessing the generalizability of randomized trial results to target populations.","volume":"16","author":"Stuart","year":"2015","journal-title":"Prev Sci"},{"key":"R3-20261027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/1740774509103868","article-title":"The calibration of treatment effects from clinical trials to target populations.","volume":"6","author":"Frangakis","year":"2009","journal-title":"Clin Trials"},{"key":"R4-20261027","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/aje\/kwad041","article-title":"How choice of effect measure influences minimally sufficient adjustment sets for external validity.","volume":"192","author":"Webster-Clark","year":"2023","journal-title":"Am J Epidemiol"},{"key":"R5-20261027","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/add.13789","article-title":"Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse clinical trials network.","volume":"112","author":"Susukida","year":"2017","journal-title":"Addiction"},{"key":"R6-20261027","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/sim.8426","article-title":"Extending inferences from a randomized trial to a new target population.","volume":"39","author":"Dahabreh","year":"2020","journal-title":"Stat Med"},{"key":"R7-20261027","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/aje\/kwaa270","article-title":"Study designs for extending causal inferences from a randomized trial to a target population.","volume":"190","author":"Dahabreh","year":"2021","journal-title":"Am J Epidemiol"},{"key":"R8-20261027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/aje\/kwq084","article-title":"Generalizing evidence from randomized clinical trials to target populations: the ACTG 320 trial.","volume":"172","author":"Cole","year":"2010","journal-title":"Am J Epidemiol"},{"key":"R9-20261027","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10654-019-00533-2","article-title":"Extending inferences from a randomized trial to a target population.","volume":"34","author":"Dahabreh","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"R10-20261027","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/EDBK_243729","article-title":"Overcoming barriers to clinical trial enrollment.","volume":"39","author":"Nipp","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R11-20261027","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction.","volume":"377","author":"Erlinge","year":"2017","journal-title":"N Engl J Med"},{"key":"R12-20261027","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/hrt.2010.198804","article-title":"The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART).","volume":"96","author":"Jernberg","year":"2010","journal-title":"Heart"},{"key":"R13-20261027","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence.","volume":"110","author":"Booth","year":"2014","journal-title":"Br J Cancer"},{"key":"R14-20261027","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/biom.13009","article-title":"Generalizing causal inferences from individuals in randomized trials to all trial-eligible individuals.","volume":"75","author":"Dahabreh","year":"2019","journal-title":"Biometrics"},{"key":"R15-20261027","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/aje\/kwae353","article-title":"Single world intervention graphs (SWIGs): a practical guide.","volume":"194","author":"Bezuidenhout","year":"2024","journal-title":"Am J Epidemiol"},{"key":"R17-20261027","first-page":"39","article-title":"Causal survival analysis: a guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence.","volume":"2","author":"Murray","year":"2020","journal-title":"Res Methods Med Health Sci"},{"key":"R18-20261027","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/sim.9550","article-title":"Sensitivity analysis using bias functions for studies extending inferences from a randomized trial to a target population.","volume":"42","author":"Dahabreh","year":"2023","journal-title":"Stat Med"},{"key":"R19-20261027","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/jrsssa\/qnae012","article-title":"Sensitivity analysis for the generalization of experimental results.","volume":"187","author":"Huang","year":"2024","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"R20-20261027","article-title":"Generalizing causal inferences from randomized trials: counterfactual and graphical identification.","author":"Dahabreh","year":"2019","journal-title":"arXiv preprint arXiv:1906.10792"},{"key":"R21-20261027","article-title":"Generalizing and transporting inferences about the effects of treatment assignment subject to non-adherence.","author":"Dahabreh","year":"2022","journal-title":"arXiv preprint arXiv:2211.04876"},{"key":"R22-20261027","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/EDE.0000000000001863","article-title":"Generalizing and transporting causal inferences from randomized trials in the presence of trial engagement effects.","volume":"36","author":"Ung","year":"2025","journal-title":"Epidemiology"},{"key":"R23-20261027","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/17407745211012438","article-title":"Assessing the external validity of the VALIDATE-SWEDEHEART trial.","volume":"18","author":"Rylance","year":"2021","journal-title":"Clin Trials"},{"key":"R24-20261027","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1214\/16-AOAS1001","article-title":"Sensitivity analysis for an unobserved moderator in RCT-to-target-population generalization of treatment effects.","volume":"11","author":"Nguyen","year":"2017","journal-title":"Ann Appl Stat"}],"container-title":["Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/EDE.0000000000001994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T11:00:13Z","timestamp":1793098813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/EDE.0000000000001994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ede.0000000000001994","relation":{},"ISSN":["1044-3983","1531-5487"],"issn-type":[{"value":"1044-3983","type":"print"},{"value":"1531-5487","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}